semaglutide death Obesity with established CVD: now indicated to reduce CV death, MI, and stroke Ozempic cuts risk of death

The economics of compounded preparations deserve closer examination

Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone

dolor de cabeza o sensacin de presin

At Prima Urgent Care, Njomo provides personalized guidance throughout your weight loss journey

R.NettoL